A Wednesday night earnings report left big questions about how the spending reductions would affect the company.

Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 8.5% in the pre-market session after the company reported ...

Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The ...

Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...

On Wednesday, 10x Genomics Inc (NASDAQ:TXG) reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of ...

Stifel lowered the firm’s price target on 10x Genomics (TXG) to $18 from $21 and keeps a Buy rating on the shares. The funding environment ...

Biotech company 10x Genomics (NASDAQ:TXG) will be reporting earnings tomorrow after market hours. Here’s what to look for.

Genomics (TXG) delivered earnings and revenue surprises of -25% and 0.03%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results ...

2025 Stock Picks. In this article, we are going to take a look at where 10x Genomics, Inc. (NASDAQ:TXG) stands against the other stocks in Cathie Wood’s portfolio. Cathie Wood is one of Wall ...